Kartos Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.kartosthera.com
Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Conditions
- MyelofibrosisPost-ET MyelofibrosisPrimary MyelofibrosisPost-PV MFMF
- Interventions
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT06479135
- Locations
- 🇦🇺
St George Hospital, Kogarah, Australia
🇺🇸Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States
🇺🇸Medical Oncology Hematology Consultants, PA, Newark, Delaware, United States
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Conditions
- Endometrial Cancer
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 268
- Registration Number
- NCT05797831
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸Texas Oncology-San Antonio Medical Center, San Antonio, Texas, United States
🇺🇸Kaiser Permanente Center, Vallejo, California, United States
Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Registration Number
- NCT05705466
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
- Conditions
- Small-cell Lung CancerSmall Cell Lung CarcinomaSmall Cell Lung Cancer Extensive StageSmall Cell Lung Cancer Recurrent
- Interventions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT05027867
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Spain
🇫🇷EDOG - Institut Bergonie - PPDS, Bordeaux, France
🇪🇸Hospital General Universitario de Alicante, Alicante, Spain
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
- Conditions
- Primary Myelofibrosis (PMF)Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04878003
- Locations
- 🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States
🇺🇦City Hematology Center of Municipal Non-Profit Enterprise City Clinical Hospital #4 of Dnipro City Council, Dnipro, Ukraine
🇧🇾Minsk Scientific and Practice Center of Surgery, Transplantology and Hematology, Minsk, Belarus
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT04835584
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇮🇹Azienda Ospedaliero - Universitaria Mater Domini, Catanzaro, Italy
🇮🇹Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF
- Conditions
- Primary MyelofibrosisPost-ET MyelofibrosisMyelofibrosisPost-PV MF
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT04640532
- Locations
- 🇫🇷
CHU Nantes - Hôtel Dieu, Nantes, France
🇭🇺Medical Center of the University of Pecs, 1st Department of Internal Medicine, Division of Hematology, Pécs, Hungary
🇵🇱Nasz Lekarz Medical Outpatient Clinics Slawomir Jeka, Toruń, Poland
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- Conditions
- Chronic Lymphocytic LeukemiaNon Hodgkin LymphomaDiffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT04502394
- Locations
- 🇰🇷
Seoul St. Mary's Hospital, Seoul, Korea, Republic of
🇵🇱Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii, Gdansk, Poland
🇵🇱Copernicus PL Sp. z o.o., Wojewodzkie Centrum Onkologii, Gdańsk, Poland
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04485260
- Locations
- 🇫🇷
Institut Paoli-Calmettes, Marseille, France
🇵🇱Oddział Kliniczny Hematologii Szpitala Uniwersyteckiego w Krakowie, Kraków, Poland
🇵🇱Szpital Wojewódzki w Opolu Sp zooOddzial Kliniczny Hematologii, Opole, Poland
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
- Interventions
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT04113616
- Locations
- 🇩🇪
University Hospital Jena, Jena, Germany
🇧🇪Cliniques universitaires Saint-Luc, Brussels, Belgium
🇧🇪UZ Gent, Ghent, Belgium